News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Gilead Sciences, Inc. AIDS Drug Safe for HIV Prevention in Study
July 23, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Gilead's (GILD.O) HIV drug tenofovir is safe to be given to men at high risk of contracting the virus as a preventative measure, scientists said on Friday, but further trials are needed to test its efficacy.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Gilead Sciences, Inc.
MORE ON THIS TOPIC
Insights
Inside Germany’s biotech capital infrastructure and innovation engine
May 21, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Deals
Lilly and Engage Bio tie the knot with $202M acquisition
May 20, 2026
·
2 min read
·
Gabrielle Masson
Drug Development
Beam one-ups Wave as both show promise of genetic editing for AATD
May 20, 2026
·
2 min read
·
Tristan Manalac
Immunology and inflammation
AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis
May 20, 2026
·
2 min read
·
Tristan Manalac